The AJMC® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.
May 15th 2024
Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women's Health Week and every week.
Dr Adriaan Voors Discusses Initiating SGLT2 Inhibitors During Hospitalization
November 16th 2021Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, addresses the lack of prescribing for sodium-glucose co-transporter 2 (SGLT2) inhibitors during hospitalization for acute heart failure by highlighting their benefits and that they are part of guideline-directed treatment.
Watch
Mortality Increase Seen in Patients With Heart Failure, Hypercapnia
November 10th 2021Outcomes of in-hospital mortality, 7-day mortality, and emergency department length of stay were investigated among a cohort of patients with acute heart failure and hypercapnia, or excessive levels of CO2 in the blood.
Read More
Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI
November 2nd 2021Individuals with a history of acute myocardial infarction (AMI), or heart attack, may benefit on several fronts following early administration of the neprilysin inhibitor/angiotensin receptor blocker sacubitril/valsartan.
Read More
SGLT2 Inhibitors, GLP-1 RAs Featured in Prevention Guidelines
October 4th 2021The prevention document, released during ESC Congress 2021, marked the first update of this section of the guidelines in 8 years. It featured changes that reflect the arrival of a pair of drug classes with proven benefits in CV outcomes but that experts say are underutilized.
Read More
Dr Deepak L. Bhatt: There Is a Lot of Excitement for HFpEF Right Now
October 1st 2021In an interview for ESC Congress 2021, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, describes the treatment outlook for patients with heart failure with preserved ejection fraction (HFpEF).
Watch
HIIT Improves Cardiorespiratory Fitness More Than Low-Intensity Exercise, Review Says
September 26th 2021For patients with heart failure and cardiovascular disease, high intensity interval training has a greater positive effect on cardiorespiratory fitness than moderate intensity continuous training.
Read More
Remove Race From Equation Used to Assess Kidney Function, Researchers Say
September 23rd 2021Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.
Read More
Dr Stefan Anker: Patients With HFpEF Deserve a New Treatment
September 21st 2021With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.
Watch
Diagnosis Patterns and Stress Testing Trends After Implementing High-Sensitivity Troponin Assay
This study found that switching from a conventional troponin assay to a high-sensitivity troponin assay resulted in changes to diagnosis patterns and stress testing trends.
Read More
Panel Outlines Updates on HF Treatment Developments, Recommendations for Guidelines
September 13th 2021In a panel at the 5th annual Heart in Diabetes Conference, John McMurray, MD, and Javed Butler, MD, highlighted recent pharmacological developments in heart failure (HF) and offered insights on overlooked areas in the field.
Read More
Dr Javed Butler Discusses the Possibility of HFpEF Combination Treatment
September 7th 2021Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.
Watch
Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States
September 4th 2021Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
Watch
STEP Trial Findings Build on SPRINT Results, With a Twist
September 2nd 2021STEP findings build on those from the SPRINT trial, seemingly confirming that intensive treatment for hypertension can reduce the risk of serious adverse cardiovascular (CV) outcomes. However, there was no significant benefit toward risk for all-cause and CV-related mortality.
Read More
Better Screening Efforts Needed for Patients With T2MI, Heart Failure
August 26th 2021Although there is an established link between type 2 myocardial infarction (T2MI) and elevated rates of cardiovascular events, less is known about the connection between T2MI and heart failure—which this new study investigated.
Read More
History of Malaria May Indicate Greater Risk of Heart Failure
August 6th 2021Individuals with a history of Plasmodium falciparum protozoan parasitic infection had a significantly increased long-term risk of developing heart failure but not myocardial infarction or cardiovascular or all-cause death.
Read More
Dr Mariana Garcia: We Cannot Overlook the Influence of Psychological Distress on Our Patients
August 3rd 2021The pandemic has exacerbated not only cardiovascular care, but also the mental health of patients, noted Mariana Garcia, MD, cardiology fellow in the Academic Clinical Investigator Pathway at Emory University and member of T32, Multidisciplinary Research Training to Reduce Inequalities in Cardiovascular Health (METRIC).
Watch
Management of Obesity in Heart Patients Needs More Attention, Study Finds
July 28th 2021The study found that more than a third of patients who were obese said they did not receive advice on physical activity or nutrition in order to lose weight, and nearly 1 in 5 said they were not even told they were overweight.
Read More
Dr Clyde Yancy: We Must Continue to Explore Why SGLT2 Inhibitors Are Effective in HF
July 27th 2021We do not yet know the exact mechanism of action of sodium glucose co-transporter-2 (SGLT2) inhibitors in heart failure (HF), but there are many exciting pssibilities, stated Clyde W. Yancy, MD, MSc, of Northwestern University’s Feinberg School of Medicine.
Watch
Dr Mikhail N. Kosiborod: DARE-19 Results Do Not Support SGLT2 Treatment Discontinuation
July 20th 2021Patients should continue to be monitored while on treatment with SGLT2 inhibitors if they are being treated for comorbid type 2 diabetes and heart failure, emphasized Mikhail N. Kosiborod, MD, cardiologist, vice president of Research at Saint Luke's Health System.
Watch